Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles

Cancer immunotherapy based on antibodies targeting the immune checkpoint PD-1/PD-L1 pathway has seen unprecedented clinical responses and constitutes the new paradigm in cancer therapy. The antibody-based immunotherapies have several limitations such as high production cost of the antibodies or thei...

Full description

Bibliographic Details
Main Authors: Katarzyna Guzik, Marcin Tomala, Damian Muszak, Magdalena Konieczny, Aleksandra Hec, Urszula Błaszkiewicz, Marcin Pustuła, Roberto Butera, Alexander Dömling, Tad A. Holak
Format: Article
Language:English
Published: MDPI AG 2019-05-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/24/11/2071